Organon (NYSE:OGN) completed an independent Audit Committee review that found no improper conduct or need to restate its financial statements. The company also presented new real world healthcare data ...

Sun Pharma’s $11.75 billion Organon acquisition was much bigger than a typical pharma deal. Once people looked past the ...

Jersey City-based Organon announced Sept. 18 it entered into an agreement to acquire Dermavant Sciences Ltd. in a $1.2 billion deal. The terms of the deal include an upfront payment of $175 million ...

Sun Pharma’s proposed $11.75 billion acquisition of Organon could reshape its global growth strategy by strengthening its ...

India’s largest drugmaker is building a wider presence beyond traditional generics, backed by specialty therapies, pipeline ...

After surging 119.70% so far in April, Organon & Co. (NYSE:OGN) secures a spot on our list of the mid-cap stocks with the highest gains in April. On April 26, 2026, Sun Pharmaceutical Industries ...

With the purchase of Organon & Co., billionaire Dilip Shanghvi's Sun Pharmaceutical Industries' annual revenue will more than double to $12.4 billion and make it one of the world’s top 25 drugmakers.

Sun Pharma's acquisition of Organon as a transformational deal, doubling revenue to USD 12 billion with 30 per cent EBITDA margin, analysts.

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal ...

Sun Pharmaceutical Industries Ltd. has agreed to acquire New York-listed women’s health-care company Organon & Co., expanding ...

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to include ...

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies ...